Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels by Gregory M. Martin et al.
REVIEW ARTICLE
published: 24 December 2013
doi: 10.3389/fphys.2013.00386
Pharmacological rescue of trafficking-impaired
ATP-sensitive potassium channels
Gregory M. Martin , Pei-Chun Chen , Prasanna Devaraneni and Show-Ling Shyng*
Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, OR, USA
Edited by:
Harley T. Kurata, University of British
Columbia, Canada
Reviewed by:
Mark Dunne, The University of
Manchester, UK
Blanche Schwappach, University
Medicine Göttingen, Germany
Carol Vandenberg, University of
California, Santa Barbara, USA
*Correspondence:
Show-Ling Shyng, Department of
Biochemistry and Molecular Biology,
Oregon Health & Science University,
L224, 3181 SW Sam Jackson Park
Road, Portland, OR 97239, USA
e-mail: shyngs@ohsu.edu
ATP-sensitive potassium (KATP) channels link cell metabolism to membrane excitability
and are involved in a wide range of physiological processes including hormone secretion,
control of vascular tone, and protection of cardiac and neuronal cells against ischemic
injuries. In pancreatic β-cells, KATP channels play a key role in glucose-stimulated insulin
secretion, and gain or loss of channel function results in neonatal diabetes or congenital
hyperinsulinism, respectively. The β-cell KATP channel is formed by co-assembly of four
Kir6.2 inwardly rectifying potassium channel subunits encoded by KCNJ11 and four
sulfonylurea receptor 1 subunits encoded by ABCC8. Many mutations in ABCC8 or
KCNJ11 cause loss of channel function, thus, congenital hyperinsulinism by hampering
channel biogenesis and hence trafficking to the cell surface. The trafficking defects
caused by a subset of these mutations can be corrected by sulfonylureas, KATP
channel antagonists that have long been used to treat type 2 diabetes. More recently,
carbamazepine, an anticonvulsant that is thought to target primarily voltage-gated sodium
channels has been shown to correct KATP channel trafficking defects. This article reviews
studies to date aimed at understanding the mechanisms by which mutations impair
channel biogenesis and trafficking and the mechanisms by which pharmacological ligands
overcome channel trafficking defects. Insight into channel structure-function relationships
and therapeutic implications from these studies are discussed.
Keywords: ATP-sensitive potassium channel, pharmacological chaperone, sulfonylurea, carbamazepine, congenital
hyperinsulinism (CHI)
INTRODUCTION
ATP-sensitive potassium channels (KATP) are a unique class of ion
channels expressed in a variety of tissues including the pancreas,
various regions of the brain, and cardiac, skeletal, and vascular
smooth muscle (Aguilar-Bryan et al., 1998). By regulating K+
flux at the plasma membrane, they function as molecular sensors
that couple cell metabolism to changes in membrane excitability
(Nichols, 2006). The KATP channel is a hetero-octamer formed
by a complex of two distinct protein subunits in 1:1 stoichiome-
try: an inwardly rectifying K+ channel Kir6.1/6.2 and a regulatory
sulfonylurea receptor SUR1 or SUR2 (Inagaki et al., 1995, 1997;
Clement et al., 1997; Shyng and Nichols, 1997). The “classic”
channel subtype is composed of a tetramer Kir6.2, which forms
the K+-conducting pore, with four surrounding SUR1molecules,
which provide regulatory functions.
In pancreatic β-cells, where KATP channels are best stud-
ied, they act as a key link in glucose-induced insulin secretion
(Aguilar-Bryan and Bryan, 1999; Ashcroft, 2005). In these cells,
fluctuations in the [ATP]/[ADP] ratio, brought about by changes
in blood glucose levels, push the equilibrium of KATP channels
Abbreviations: CBZ, carbamazepine; CF, cystic fibrosis; CFTR, cystic fibrosis
transmembrane conductance regulator; CHI, congenital hyperinsulinism; KATP,
ATP-sensitive potassium channel; Kir6.2, inwardly rectifying potassium channel
6.2; NBD, nucleotide binding domain; PNDM, permanent neonatal diabetes; SU,
sulfonylureas; SUR1, sulfonylurea receptor 1; TMD, transmembrane domain.
toward the closed or open state. Thus, when blood glucose lev-
els rise, the intracellular [ATP]/[ADP] ratio also rises, blocking
K+ efflux through KATP channels. This depolarizes the β-cell and
opens voltage-gated Ca2+ channels; the subsequent Ca2+influx
then triggers exocytosis of insulin secretory granules. When blood
glucose levels fall, the intracellular [ATP]/[ADP] ratio will fall,
pushing the equilibrium toward open KATP channels, repolarizing
the β-cell and blocking further insulin release (Figure 1).
Not surprisingly, mutations in the genes encoding KATP chan-
nel subunits (ABCC8 for SUR1 and KCNJ11 for Kir6.2) often
lead to a breakdown in glucose homeostasis. In general, muta-
tions in KATP genes are classified as either gain-of-function,
where constitutively open channels preclude insulin secretion,
or loss-of-function, non-functional channels that are unable
to hyperpolarize the β-cell and cause persistent insulin release
(Aguilar-Bryan and Bryan, 1999; Hattersley and Ashcroft, 2005).
Over the past 15 years, a number of groups have identified a
class of loss-of-function mutations in the genes encoding the
KATP channel, particularly in ABCC8 (SUR1), that interfere with
proper biogenesis and trafficking, thus, preventing normal sur-
face expression of the channel (Cartier et al., 2001; Partridge et al.,
2001; Taschenberger et al., 2002; Crane and Aguilar-Bryan, 2004;
Tornovsky et al., 2004; Yan et al., 2004, 2007; Taneja et al., 2009).
These mutations are collectively referred to as trafficking muta-
tions. Studies have demonstrated that congenital hyperinsulinism
of infancy (CHI), a rare disease characterized by persistent insulin
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FIGURE 1 | KATP channels regulate insulin secretion in pancreatic β-cells.
Under conditions of low blood glucose, the relatively low ATP/ADP ratio in
the β-cell promotes opening of KATP channels, keeping β-cell membrane
potential at a hyperpolarized state to prevent Ca2+ influx and insulin release.
Upon an increase in blood glucose, β-cells increase glucose uptake through
GLUT2 transporters; glycolysis and respiration then elevate the intracellular
ATP/ADP ratio and close KATP channels. This causes depolarization of the
plasma membrane potential which opens voltage-gated Ca2+ channels; the
subsequent influx of Ca2+ initiates fusion of insulin secretory granules with
the plasma membrane.
secretion even under severe hypoglycemia (Stanley, 1997), is fre-
quently caused by trafficking mutations in KATP channel genes. In
these patients, channel subunits are synthesized but fail to reach
the plasma membrane, mostly due to a disruption in the fold-
ing or oligomeric assembly process. The result is a constitutively
depolarized β-cell with unregulated levels of insulin release. In
many cases, the current therapy for these patients relies on par-
tial or subtotal pancreatectomy to avoid permanent consequences
of chronic hypoglycemia, which could lead to life-long insulin
dependency.
Protein misfolding and mistrafficking resulting from genetic
mutations underlie many human diseases. A prominent example
is the F508-CFTR (cystic fibrosis transmembrane conductance
regulator) deletion mutation (Riordan et al., 1989), which is
present in the majority of cystic fibrosis (CF) patients and causes
defective folding, thereby inhibiting trafficking of the protein to
the plasma membrane (Cheng et al., 1990). Small-molecule cor-
rectors, termed pharmacological chaperones, which specifically
bind to a protein and enable its proper folding and localization,
have been shown to correct trafficking defects in multiple disease-
causing proteins, like F508-CFTR (Hanrahan et al., 2013). In
some cases, mutant proteins rescued to the correct cellular loca-
tions exhibit full or partial function to reverse disease phenotypes
(Powers et al., 2009). Recent work has demonstrated that phar-
macological chaperones may also hold promise in correcting
trafficking-impaired KATP channels, offering new hope in the
treatment of CHI.
In this review, we will discuss progress to date in defining the
mechanisms by which mutations impair the biogenesis and traf-
ficking of KATP channels and how these trafficking defects can
be overcome using pharmacological approaches. In particular,
we will describe the challenges facing pharmacological rescue of
trafficking-impaired ion channels, and discuss the promises this
area holds in the treatment of disease.
MOLECULAR COMPOSITION OF KATP CHANNELS
The KATP channel is a large hetero-octamer of nearly 950 kDa,
composed of four Kir6.2 and four SUR1 subunits (Clement et al.,
1997) (Figure 2). A low-resolution cryo-EM structure indicates a
compact configuration, 18 nm across and 13 nm in height, with
a central tetrameric Kir6.2 core which forms the K+-conducting
pore, embraced by four SUR1 proteins (Mikhailov et al., 2005).
Kir6.2 is a member of the potassium inward rectifier family
(Kir). These channels have a greater tendency to allow ion flow
into, rather than out of the cell owing to block by intracellular
polyamines and Mg2+ at positive membrane potentials (Lopatin
et al., 1994). In the case of weak inward rectifiers such as Kir6.2,
the extent of intracellular block is less pronounced due to lack
of strong binding sites for the positively charged blockers. Under
most physiological conditions where membrane potential is posi-
tive to the equilibrium potential of K+ (EK), Kir channels generate
small outward currents to keep membrane potential near the
EK. This makes Kir channels primary regulators of resting mem-
brane potential in cells that express them. Importantly, many Kir
channels are ligand-gated, endowing them the ability to couple
specific physiological signals to membrane excitability (Nichols
and Lopatin, 1997). For the Kir6.2-SUR1 KATP channel com-
plex, gating regulation by intracellular nucleotides ATP and ADP
underlies its physiological function of coupling cell metabolism
to cell excitability.
No definitive high resolution structure for Kir6 channels yet
exists. However, homology modeling using crystal structures of
eukaryotic and prokaryotic Kir channels has provided the basis
for a structural model (Capener et al., 2000; Loussouarn et al.,
2001). Thus, four Kir6.2 subunits combine to form the K+ pore.
Each subunit has two transmembrane domains, M1 andM2, with
intracellular N- and C-termini. Lying perpendicular to M1 and
M2 is the short amphipathic “slide helix,” which links M1 to the
short N-terminal domain. Mutagenesis studies have implicated
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FIGURE 2 | Molecular composition and regulation of KATP channels.
Pancreatic KATP channels are hetero-octamers of four Kir6.2 subunits,
which form the K+ conducting pore, and four regulatory SUR1 subunits.
Shown on the top are transmembrane topologies of the two subunits.
SUR1 has three transmembrane domains, TMD0, TMD1, and TMD2, two
cytoplasmic nucleotide binding domains, NBD1 and NBD2, and a
cytoplasmic linker L0 that connects TMD0 to the ABC core structure of the
protein. Kir6.2 has two transmembrane helices, M1 and M2, and
cytoplasmic N- and C-terminus. Physiological and pharmacological ligands
that impact channel function are shown below. Mg-nucleotides interact
with NBDs of SUR1 to activate the channel, whereas ATP binding at Kir6.2
closes the channel. PIP2 and LC acyl CoAs also interact with Kir6.2 but
stimulate channel activity. Sulfonylureas and glinides inhibit, whereas
diazoxide stimulates channel activity by interacting with primarily SUR1. For
detailed discussion on the involvement of each subunit in channel
regulation by the various physiological and pharmacological ligands please
refer to the main text. Locations of the RKR motifs in SUR1 and Kir6.2 are
marked. Y230 and S1238, SUR1 residues critical for site B and site A of the
glibenclamide binding pocket are also marked.
this region in channel gating (Proks et al., 2004; Lin et al., 2006b;
Li et al., 2013). Interspersing M1 and M2 is an extracellular linker
followed by a pore-forming loop, constituting the selectivity filter,
the region responsible for K+ ion specificity. The M2 helix con-
nects to the large intracellular C-domain. This region constitutes
nearly half of the protein, and mediates extensive interactions
with adjacent Kir6.2 subunits (Antcliff et al., 2005).
SUR1 is a member of the ATP Binding Cassette (ABC)-C
family of transporters, and is closely related to CFTR and MRP
(multi-drug resistance related proteins). Homology modeling has
been challenging without a solved structure for an ABC pro-
tein with significant sequence identity. Nonetheless, biochemical,
electrophysiological, and mutagenesis studies have provided the
essential topology and domain organization (Aguilar-Bryan et al.,
1995; Tusnady et al., 1997; Conti et al., 2001) (Figure 2). As an
ABC transporter, SUR1 has the core ABC structure of two trans-
membrane domains (TMD1 and TMD2), each consisting of 6
transmembrane helices. Each TMD is linked to a cytoplasmic
nucleotide-binding domain (NBD1 and NBD2) by intracellu-
lar coupling domains (ICDs), α-helical extensions of the TMDs.
Additionally, SUR proteins contain an N-terminal TMD0 domain
of five transmembrane helices, plus a long cytoplasmic loop L0,
linking TMD0 with the core ABC structure. TMD0 is absent
from most ABC transporters, including CFTR, and seems to play
a unique and interesting role in KATP channel biology. Studies
implicate TMD0 in mediating interactions between SUR1 and
Kir6.2 andmodulating forward trafficking and gating of the chan-
nel (Schwappach et al., 2000; Babenko and Bryan, 2003; Chan
et al., 2003). Another interesting point regarding SUR1 is the fact
that this ABC-C transporter has no known function as a trans-
porter; its role is strictly regulatory with regard to Kir6.2, at least
in the systems examined so far. How these two proteins evolved
to form a functional channel complex is a fascinating question.
BIOGENESIS AND TRAFFICKING REGULATION OF KATP
CHANNELS
Biogenesis and assembly of KATP channel proteins occurs in
the ER (Zerangue et al., 1999). Not much is known regarding
the events that couple translation of KATP channel subunits to
insertion in the ER membrane however, or regarding details of
the assembly process and molecular chaperones involved. When
either SUR1 or Kir6.2 is expressed alone in heterologous systems,
the subunits cannot escape the ER (Zerangue et al., 1999) and are
presumably cleared through ER-associated degradation (ERAD),
suggesting that assembled complexes are required for forward
trafficking and surface expression. Yan et al. confirmed that ubiq-
uitin and proteasome-mediated ERAD is a primary check on
KATP channels during biogenesis and that this process in part
regulates the surface expression of KATP channels as inhibition
of proteasome function led to an increase in surface expression
of the channel (Yan et al., 2005). More recently, Wang and col-
leagues showed that Derlin-1, an ER membrane protein involved
in recognition or retrotranslocation of substrates out of the ER for
ERAD (Lilley and Ploegh, 2004; Ye et al., 2004), forms a complex
with SUR1 and Kir6.2 and is also an important factor determining
surface levels of KATP channels (Wang et al., 2012). SUR1 is a gly-
coprotein, containing twoN-linked glycosylation sites. Conti et al.
mutated these sites in SUR1 and observed ER retention of the
protein, suggesting that lectin chaperones calnexin/calreticulin,
which are known to assist the folding of glycoproteins, participate
in the folding and assembly of KATP channels (Conti et al., 2002).
Yan et al. also demonstrated that the molecular chaperone Hsp90
participates in the folding of KATP channels by interacting with
SUR1, and that knockdown of Hsp90 reduced surface expres-
sion of the channel (Yan et al., 2010). These studies only begin
to address the sequence of events and the mechanisms that gov-
ern the folding/assembly and degradation of the KATP channel,
and represent important first steps in understanding this critical
aspect of KATP channel biology.
ASSEMBLY DOMAINS
A central question in understanding channel biogenesis is what
are the assembly domains on the subunits themselves that direct
this process? Using chimeras of Kir2.1, which is known to not
associate with SUR1, and Kir6.2, Giblin et al. looked for mini-
mal domains necessary for interactions between Kir6.2 and SUR1
(Giblin et al., 1999). They found that a proximal region (amino
acids 208–279) in the Kir6.2 C-terminus is necessary for co-
immunoprecipitation of the two subunits but this region is not
sufficient to mediate formation of KATP functional channel com-
plexes as no channel activity could be detected at the cell surface.
Schwappach et al., with a similar approach using chimeras of
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Kir6.2 and Kir2.1 demonstrated theM1 and N-terminus of Kir6.2
are involved in KATP channel assembly and gating (Schwappach
et al., 2000).
One particularly interesting assembly domain of the KATP
channel is TMD0, the first bundle of transmembrane helices
in SUR1. This domain, coupled with the first intracellular loop
L0, is largely unique to SUR proteins; most eukaryotic ABC
transporters have only the core structure of TMD1 and TMD2
with the two intracellular nucleotide binding domains NBD1
and NBD2 (Tusnady et al., 1997). Using chimeric SUR1 pro-
teins containing TMD0 from another ABC transporter MRP1
known to not interact with Kir6.2, Schwappach et al. first demon-
strated a role of TMD0 inmediating subunit interactions between
Kir6.2 and SUR1 and in promoting forward trafficking of Kir6.2
(Schwappach et al., 2000). Subsequent work by others showed
that in truncated Kir6.2 subunits (see below), TMD0 alone
will increase surface expression of Kir6.2 and produce so-called
“mini-KATP” channels that display single-channel kinetics sim-
ilar to WT channels, but are unresponsive to metabolic signals
and pharmacological ligands (Babenko and Bryan, 2003; Chan
et al., 2003). Studies utilizing naturally occurring TMD0 muta-
tions present in patients with CHI have identified residues which
may be crucial for folding or subunit interactions (Chan et al.,
2003; Yan et al., 2004, 2007; Pratt et al., 2011), but the pre-
cise nature of the interface of TMD0 with Kir6.2 remains to be
elucidated.
EXITING THE ER
As mentioned, forward trafficking and surface expression of KATP
channels relies on assembly of both subunits in the ER. This
makes Kir6.2 unique among Kir channels, thereby prompting
studies to define the domain responsible for ER retention of
unassembled Kir6.2 subunits. Tucker et al. first demonstrated
that C-terminal truncations of 25 or 36 amino acids in Kir6.2
allowed for potassium currents in the absence of SUR1 (Tucker
et al., 1997). Later work by Zerangue et al. utilized this semi-
nal discovery in mapping the particular retention motif within
the C-terminus of Kir6.2 and identified a tripeptide RKR local-
ization signal (Zerangue et al., 1999) which was found to also
function in SUR1 (Figure 2). The current model suggests these
motifs must be masked during the assembly of the channel com-
plex to allow forward trafficking to proceed. Unassembled or
misassembled subunits are thus prevented from reaching the
plasma membrane, allowing for quality control in the KATP bio-
genesis pathway. Questions still remain regarding the mechanism
of how the RKR motifs function in ER retention. A study by
Yuan et al using an artificial reporter construct first brought
forth a model whereby an interplay between the 14-3-3 fam-
ily of proteins and the coatamer complex 1 (COPI) acts to
regulate ER to Golgi trafficking via interactions with the RKR
motifs (Yuan et al., 2003). Their group showed that COPI pro-
teins can specifically bind the RKR motif in Kir6.2. The same
study demonstrated 14-3-3 proteins can also recognize the sig-
nal when multiple subunits are present. The model proposes
that COPI proteins recognize RKR motifs on misassembled or
unassembled subunits and promote their retrieval to the ER.
The 14-3-3 proteins, by contrast, act as sensors for assembled
subunits, and can bind properly assembled complexes and pre-
vent recognition of their RKR motifs by COPI, allowing forward
trafficking to proceed. A later study from the same lab using the
14-3-3 scavenger approach further substantiated a role of 14-3-3
proteins in regulating trafficking and surface expression of het-
erologously and endogenously expressed KATP channels (Heusser
et al., 2006).
Anterograde, or forward trafficking signals on KATP channel
subunits have been more challenging to define. While TMD0
clearly facilitates Kir6.2 expression, it can only do so when
co-expressed with Kir6.2C26, a C-terminal deletion construct
missing the last 26 amino acids, in which the RKR motif resides
(Chan et al., 2003). TMD0, therefore, is not the domain shield-
ing the RKR signals from COPI proteins. Sharma et al. (1999)
identified a putative forward trafficking signal in the distal C-
terminus of SUR1 by making SUR1 constructs missing varying
numbers of residues in the C-terminus (Sharma et al., 1999).
However, another study showed that larger deletions in the SUR1
C-terminus had no effect on channel expression, making the
existence of the C-terminal forward trafficking signal debatable
(Giblin et al., 2002). No studies to date have resolved this issue or
confirmed the existence of a bona fide anterograde signal on either
subunit.
Interestingly, studies examining the kinetics of the biogene-
sis pathway using metabolic pulse-chase labeling have demon-
strated the intrinsic inefficiency of KATP assembly, estimating that
only about 20% of newly synthesized SUR1 or Kir6.2 actually
forms mature complexes, with the remaining pool being rapidly
degraded (Yan et al., 2004, 2005, 2010; Chen et al., 2011). CFTR
and other ABC transporters also display a similar level of effi-
ciency (Ward and Kopito, 1994). Yan et al. have shown that both
SUR1 and Kir6.2 exhibit a biphasic degradation profile when
expressed alone, each containing a fast and a slow component
(Yan et al., 2004, 2005). Crane and Aguilar-Bryan also observed
biphasic degradation of Kir6.2 expressed alone; however, they
reported remarkable stability of SUR1 expressed alone (∼25 h)
(Crane and Aguilar-Bryan, 2004). These differences may be due
to technical reasons or experimental conditions. Nevertheless,
both groups saw increased stability of SUR1 and Kir6.2 when the
two subunits were co-expressed, suggesting the subunits become
more stable upon mulitimeric assembly (Crane and Aguilar-
Bryan, 2004; Yan et al., 2005). While some differences are yet
to be resolved, studies like these address fundamental aspects of
KATP channel biology not by looking at snapshots, but by getting
the dynamics involved in the biogenesis pathway. Many questions
remain unanswered: How are nascent polypeptides recognized in
the cytosol and translocated in the ER? What is the sequence of
events involving folding and assembly of KATP channel subunits?
Is folding co- or post-translational?What protein-protein interac-
tions occur in the ER that guide this process, and what molecular
chaperones are involved? What routes do KATP channels take after
exiting the ER? Obviously much work needs to be done, but
answers to these questions will provide a deep level of insight
into how large, multimeric membrane proteins are assembled,
and importantly, will allow researchers to more fully understand
mechanisms of proteostasis and trafficking diseases, like CHI
or CF.
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GATING REGULATION OF KATP CHANNELS
It is well-understood that the primary mode of physiological
regulation of KATP channel function is through the opposing
inhibitory action of ATP and stimulatory action of MgADP. The
bulk ATP concentration is relatively stable in most cells, how-
ever, raising doubt that ATP can serve as a primary regulator
of the channel. In β-cells, ATP concentrations have been esti-
mated to change from 2 to 4mM when glucose is elevated from
0 to 10mM (Detimary et al., 1998); such high levels of ATP are
expected to prevent channel opening even at the lowest glucose
concentrations. However, the small changes in [ATP], coupled
with much larger changes in ADP levels in the opposite direction
as glucose concentrations fluctuate, result in significant changes
in the [ATP]/[ADP] ratio (Nilsson et al., 1996; Detimary et al.,
1998) to shift the apparent ATP sensitivity and effectively regu-
late channel activity (Tarasov et al., 2004). Thus, when glucose
levels are low, MgADP stimulation will predominate, KATP chan-
nels will be open, the cell will be hyperpolarized, and no insulin
will be secreted. When glucose levels are high, ATP inhibition will
take over, closing KATP channels, causing membrane depolariza-
tion, opening voltage-gated Ca2+ channels and triggering insulin
exocytosis.
In the absence of ATP, KATP channels display so-called burst
kinetics, characterized by periods of rapid openings and closings
separated by long closed intervals (Alekseev et al., 1997). ATP
inhibition of KATP channels, involving non-hydrolytic binding
at the intracellular face of Kir6.2, acts to decrease the frequency
and length of the burst periods, and increases the duration of
the closed intervals (Babenko et al., 1999). Based on mutagenesis
and docking studies using homology models of Kir6.2, binding is
thought to occur at an interface involving the N- and C-domains
of one subunit, and the N-domain of an adjacent Kir6.2 subunit
(Antcliff et al., 2005). Each channel contains four ATP-binding
sites, yet ATP binding at a single site is sufficient to close the chan-
nel, in support of a concerted gating model (Markworth et al.,
2000; Drain et al., 2004). Interestingly, however, SUR1 sensitizes
Kir6.2 to ATP inhibition by about a factor of 10 (Tucker et al.,
1997). This could be due to allosteric effects on Kir6.2 or facilita-
tion of ATP binding by SUR1 (Babenko, 2005); at this point the
mechanism remains unclear.
Nucleotide activation occurs at the nucleotide binding
domains of SUR1 and acts to antagonize ATP inhibition (Gribble
et al., 1997). The requirement of Mg2+ in this process has
prompted studies to examine nucleotide interactions and hydrol-
ysis at the NBDs. These studies led to a proposal that hydrolysis
of MgATP to MgADP at NBD2, which contains the consensus
ATPase site, stabilizes ATP binding at NBD1, which carries a
degenerate ATPase site, and drives dimerization of the NBDs to
promote channel opening at Kir6.2 (Zingman et al., 2001; Matsuo
et al., 2005; Masia and Nichols, 2008). It is worth noting that
direct measurements of MgATP hydrolysis using purified SUR or
recombinant SUR NBDs indicate relatively poor hydrolysis effi-
ciency (Masia et al., 2005; De Wet et al., 2007), suggesting that
increased MgADP binding at NBD2 as intracellular [ADP] rises
may be sufficient to induce or stabilize conformational changes at
the NBDs to stimulate channel opening. Recent work by Ortiz
et al. using glibenclamide binding to probe switching of the
NBDs between closed and open dimer conformations supports
the notion that nucleotide hydrolysis at NBD2 is not required for
conformational switch (Ortiz et al., 2012, 2013). Physiologically,
the regulation of SUR1 in response to an increase in intracellu-
lar [ADP] is critical for repolarizing the β-cell when glucose levels
drop; without it the β-cell will be unable to stop secreting insulin.
This is one commonmechanism formutations identified in SUR1
in patients with CHI (Nichols et al., 1996a; Shyng et al., 1998),
who persistently secrete insulin even under severely low blood
glucose levels.
Membrane phosphoinositides, such as phosphatidylinositol-
4,5-bisphosphate (PIP2), and metabolic derivatives of free fatty
acids, long-chain acyl-CoA esters (LC-CoAs) also have pro-
found effects on KATP channel gating (Baukrowitz et al., 1998;
Branstrom et al., 1998; Shyng and Nichols, 1998). Both PIP2 and
LC-CoAs interact with Kir6.2 via similar mechanisms to increase
channel open probability and antagonize ATP inhibition (Schulze
et al., 2003). Mutagenesis studies indicate that PIP2 and ATP may
have overlapping but non-identical binding sites in Kir6.2 (Shyng
et al., 2000; Cukras et al., 2002a,b; Antcliff et al., 2005). While
Kir6.2 interacts directly with PIP2, SUR1 increases the sensitiv-
ity of the channel to PIP2 stimulation (Baukrowitz et al., 1998;
Shyng and Nichols, 1998). Recent work by Pratt et al. shows that
TMD0 of SUR1, which is known to increase the open probabil-
ity of Kir6.2, does so by stabilizing the interaction between Kir6.2
and PIP2 (Pratt et al., 2011). A crucial role of PIP2 in maintain-
ing channel activity in β-cells has been clearly demonstrated (Lin
et al., 2005); mutations which disrupt the channel response to
PIP2 have been identified in patients with CHI (Lin et al., 2006b,
2008). The relevance of PIP2or LC-CoAs to physiological regula-
tion of KATP activity however, is less certain (Tarasov et al., 2004),
although pathological changes in LC-CoAs have been proposed to
impact channel function (Larsson et al., 1996; Riedel and Light,
2005).
PHARMACOLOGICAL REGULATION OF KATP CHANNELS
An important class of agents which regulate KATP channels
are sulfonylureas (Aguilar-Bryan and Bryan, 1999; Gribble and
Reimann, 2003b). Discovered in the 1940s as sulfonamide drugs
that have hypoglycemic effects, sulfonylureas interact specifi-
cally with the sulfonylurea receptor SUR, giving it its namesake.
Sulfonylureas have been used in the treatment of non-insulin
dependent diabetes for decades, yet precisely how they promote
insulin release in the body remained a mystery for years. It is
nowwell understood that sulfonylureas bind directly to SUR1 and
inhibit channel activity, thus stimulating insulin release by depo-
larizing the β-cell independent of glucose. Tolbutamide was part
of the first generation of hypoglycemic compounds, later replaced
by second-generation compounds like glibenclamide, which have
100 to 1000-fold more potency in blocking KATP currents. A
related group of sulfonamide compounds, most notably diazox-
ide, also bind specifically to SUR1 but activate channels (Dunne
et al., 1989; Moreau et al., 2000). Diazoxide is part of a diverse
group of drugs that stimulate K+ currents, known as potassium
channel openers (KCOs) (Manley et al., 1993).
Although the KATP channel was first identified in cardiac
myocytes by Aki Noma in 1983 (Noma, 1983), its molecular
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identify remained uncertain for many years. Sulfonyulureas,
owing to their specificity, were used as probes in the purifica-
tion and cloning of KATP channels. Early patch-clamp experi-
ments demonstrated that sulfonylureas were specific blockers of
β-cell KATP channels, while diazoxide specifically opened them.
A significant advancement came from using labeled derivatives
of glibenclamide, [3H]glibenclamide (Kramer et al., 1988), and
later [125I]iodoglibenclamide (Aguilar-Bryan et al., 1990), which
could label a 140-kDa protein (SUR1) in isolated membranes
of various β-cell lines and led to cloning of the SUR1 gene
(Aguilar-Bryan et al., 1995). Schwanstecher et al. further used
125I-iodo-azidoglibenclamide, an azido analog of glibenclamide,
and found it would co-photolabel a 38 kDa protein in addition
to SUR1 and with the same apparent KD (Schwanstecher et al.,
1994); this species was later identified as Kir6.2 (Inagaki et al.,
1995). This provided the first evidence that the KATP channel is a
multimeric complex of Kir6.2 and SUR1.
Significant progress has since been made in defining the pre-
cise mechanism by which sulfonylureas and glinides, another
class of KATP channel inhibitors used in diabetes therapy, block
KATP channel function. All sulfonylureas and glinides demon-
strate high and low-affinity components of inhibition, such that
their dose-response curves are generally biphasic, with variable
separation between the two sites (Gribble and Reimann, 2003a).
At low concentrations, interaction with the SUR subunit results
in 50–75% reduction in current amplitude when administered to
the cytoplasmic face of membrane patches, suggesting that chan-
nels can remain open to an extent when bound to the drug. The
low-affinity component is attributed to interaction with Kir6.2,
but this only occurs at very high drug concentrations.
According to the pharmacophore model, structurally diverse
compounds can possess overlapping electronic and stereochem-
ical properties that allow them to bind a common receptor
site. SUR was proposed to bind sulfonylureas accordingly with
a bipartite binding pocket (Figure 3A). Consistent with this,
the enhanced affinity observed in glibenclamide is attributed to
interaction with the two overlapping binding sites on SUR1,
termed site A and site B (Brown and Foubister, 1984). Site A
is proposed to interact with a lipophilic group adjacent to the
negative charge of a sulfonylurea group, while site B recognizes
a lipophilic group adjacent to an amide. Glibenclamide pos-
sesses both of these moieties, while most other sulfonylureas
and hypoglycemic agents such as glinides possess one or the
other. Sulfonylureas are further distinguished by their ability
FIGURE 3 | The processing defect of SUR1 caused by TMD0 trafficking
mutations is corrected by glibenclamide and carbamazepine. (A)
Pharmacophore model for binding of various KATP channel blockers that
function as effective pharmacological chaperones, showing the chemical
moieties thought to confer affinity for either site A or site B on SUR1.
(B) Chemical structure of carbamazepine. (C) Western blot of whole cell
lysates of COSm6 cells transiently transfected with Kir6.2 plus WT or TMD0
mutant SUR1 cDNAs. SUR1, a glycoprotein, shows two bands in
immunoblots: a lower core glycosylated (immature; open arrow) form that
has not exited the ER and an upper complex-glycosylated (mature; solid
arrow) band that has trafficked through the Golgi. Incubation of cells with
glibenclamide (5μM; Glib) or carbamazepine (CBZ) for 16 h increased levels
of the mature band of TMD0 trafficking mutants compared to those treated
with DMSO (veh). The effect of carbamazepine was dose-dependent, with an
effect detectable at a concentration as low as 0.2μM. Untransfected control
is shown for comparison. Adapted from Figure 1 in Chen et al. (2013b).
Frontiers in Physiology | Membrane Physiology and Membrane Biophysics December 2013 | Volume 4 | Article 386 | 6
Martin et al. Correcting KATP channel trafficking defects
to block either SUR1 or SUR2 KATP channels. Compounds
that contain a non-sulfonylurea moiety (such as glibenclamide,
glimepiride, repaglinide) can bind with high affinity to SUR1
and SUR2, while those with only the core sulfonylurea struc-
ture (tolbutamide, gliclizide) are specific for SUR1 (Quast et al.,
2004). This difference made tolbutamide a pharmacological tool
to uncover the sulfonylurea binding (A) site. Research using
chimeric receptors of SUR1/SUR2 showed that TMD2 of SUR1
is critical for sulfonylurea binding. Further studies showed that
mutation of S1237 of the cytoplasmic loop between TMs 15
and 16 to tyrosine (the equivalent residue in SUR2) abolished
high affinity tolbutamide block and [3H]glibenclamide bind-
ing (Ashfield et al., 1999) [note that S1237 in SUR1 is now
referred to as S1238, as current sequence information for ABCC8
(GenBank reference NM_00352.2) includes the alternate exon 17
(GenBank L78208) which contains an additional amino acid].
Further, the reciprocal mutation in SUR2 (Y1206S) increased
[3H]glibenclamide binding by roughly 10-fold. Mapping of site
B in SUR1 came from a study examining affinity labeling with
[125I]iodoglibenclamde which identified a ∼50 kDa fragment
including TMD0-L0 (Bryan et al., 2004). A more precise defini-
tion came from Vila-Carriles et al. by using deletions and alanine
scanning in TMD0 and L0 of SUR1 to monitor photolabeling
by [125I]azido-iodoglibenclamide (Vila-Carriles et al., 2007). The
authors concluded that L0 of SUR1 is absolutely essential for
glibenclamide binding, while TMD0 is nonessential. Scanning
alanine mutations showed that Y230 and W232 are critical for
high affinity photolabeling. Further, they determined that the N-
terminal 33 amino acids of Kir6.2 are involved in site B labeling
by [125I]azido-iodoglibenclamide. Together, these results indicate
that site A (TMD2) and site B (L0) are within close physical prox-
imity such that they can cooperatively bind glibenclamide, and
that the N-terminus of Kir6.2 also forms part of the site B binding
pocket.
PHARMACOLOGICAL REGULATION OF KATP CHANNEL
TRAFFICKING DEFECTS
Over the past 10 years, it has been recognized that, in addition
to their action as specific KATP channel blockers, sulfonylureas
also promote the proper folding and biogenesis of trafficking-
impaired mutant SUR1 proteins identified in patients with CHI
by acting as pharmacological chaperones. They achieve this with
domain specificity, only rescuing mutations within TMD0 of
SUR1. In principle, this opened up a new therapeutic avenue for
sulfonylureas, in which they could be administered to patients
with TMD0 trafficking mutations and rescue KATP channel func-
tion in β-cells. Sulfonylureas are imperfect correctors, however, as
they often irreversibly block channel function of rescued mutant
channels. This is an unsuitable therapeutic approach for treating
diseases like CHI, which require functional channels at the cell
surface in order to limit insulin release and restore blood glucose
to normal levels. Recently, additional new compounds such as
carbamazepine (CBZ) (Figure 3B), which also correct trafficking-
impaired KATP channels with mutations in TMD0 of SUR1 with-
out the irreversible block observed with glibenclamide, have been
identified. As discussed below, in vitro studies with pharmacolog-
ical chaperones have increased our understanding of how certain
KATP channel mutations lead to disease, strengthening the link
between genotype and phenotype, while also highlighting gen-
eral principles involved in the gating and molecular assembly of
heteromeric ion channels, like KATP.
KATP CHANNEL TRAFFICKING DEFECTS IN HUMAN DISEASE
Proper cellular function relies on both the absolute number and
subcellular localization of many proteins; this is particularly true
of membrane proteins like KATP. For ion channels and other
membrane or secreted proteins, translation begins in the cytosol
but soon becomes associated with the endoplasmic reticulum
(ER). Here it is thought the bulk of protein folding and qua-
ternary assembly take place. This occurs under the auspices of
an array of molecular chaperones, integral members of the ER
quality control system, which ensure the proper folding, process-
ing, and structural integrity of nascent proteins while preventing
the accumulation of defective proteins which may disrupt normal
cell function. Trafficking mutations can interfere with this process
by disrupting protein folding and molecular assembly in the ER,
generally leading to retention and clearance of mutant proteins
through ERAD.
Mislocalization of cell-surface proteins which are otherwise
functional has been demonstrated in numerous diseases, includ-
ing CF, familial hypercholesteremia, retinitis pigmentosa, and
diabetes insipidus (Powers et al., 2009). In CF, theF508 deletion
(present in 90% of CF patients) in CFTR leads to ER retention and
rapid degradation of the incompletely processed protein by the
proteasome (Jensen et al., 1995; Ward et al., 1995). Insufficient
levels of this chloride channel at the cell surface prevent cAMP-
mediated chloride ion, water, and bicarbonate conductance in
a variety of tissues. More recently, it has been established that
point mutations in the genes encoding the KATP channel sub-
units can also interfere with or prevent proper folding and/or
molecular assembly in the ER (Table 1). These mutations are
found throughout the SUR1 and Kir6.2 proteins. Normal lev-
els of protein are usually translated, but mutant proteins are
unable to exit the ER, and as with F508-CFTR and many other
conformationally-defective proteins, are degraded through the
ubiquitin/proteasome pathway. KATP channel trafficking muta-
tions have since been shown to be a common mechanism in
CHI (Cartier et al., 2001; Taschenberger et al., 2002; Crane and
Aguilar-Bryan, 2004; Tornovsky et al., 2004; Yan et al., 2004, 2007;
Marthinet et al., 2005; Muzyamba et al., 2007; Fukuda et al., 2011;
Powell et al., 2011; Faletra et al., 2013), in which loss of KATP
channels at the cell surface results in unregulated insulin secretion
following constitutive depolarization of the β-cell.
Among the mutations documented, A116P- and V187D-
SUR1, both located in TMD0, exhibited reduced association
with Kir6.2 in co-immunoprecipitation experiments (Chan et al.,
2003), supporting a role of TMD0 in subunit-subunit inter-
actions. Further, F1388-, A116P-SUR1 and W91R-Kir6.2 all
showed accelerated degradation (Crane and Aguilar-Bryan, 2004;
Yan et al., 2004, 2005). These observations are consistent with
the mutant proteins being misfolded and/or unable to form
channel complexes. Of note, the aforementioned studies were
all conducted in mammalian cells rather than Xenopus oocytes
as oocytes cultured at a lower temperature have less stringent
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Table 1 | Congenital Hyperinsulinism-associated KATP channel
trafficking mutations and response to pharmacological rescue1.
Mutation Domain Rescue Rescue Gating References
by SU by CBZ property
SUR1
G7R TMD0 Yes Yes Normal Yan et al., 2007
N24K TMD0 Yes Yes Normal Yan et al., 2007
F27S TMD0 Yes Yes Normal Yan et al., 2007
R74W TMD0 Yes Yes ATP-
insensitive
Yan et al., 2007
A116P TMD0 Yes Yes Normal Yan et al., 2004
E128K TMD0 Yes Yes ATP-
insensitive
Yan et al., 2007
V187D TMD0 Yes Yes Normal Yan et al., 2004
R495Q TMD1 Yes Yes Unknown Yan et al., 2007
E501K TMD1 Yes Yes Unknown Yan et al., 2007
L503P TMD1 No No Unknown Yan et al., 2007
F686S NBD1 No No Unknown Yan et al., 2007
G716V NBD1 No No Unknown Yan et al., 2007
E1324K TMD2 N.D.3 N.D. Normal Faletra et al.,
2013
L1350Q NBD2 No No Unknown Yan et al., 2007
F13882 NBD2 No No MgADP-
insensitive
Cartier et al.,
2001
M1395R NBD2 N.D. N.D. Unknown Faletra et al.,
2013
R1419H NBD2 No No Unknown Tornovsky et al.,
2004
R1437Q NBD2 No No Unknown Muzyamba
et al., 2007
D1472H NBD2 No No Unknown Yan et al., 2007
R1494W NBD2 No No Unknown Tornovsky et al.,
2004
L1544P2 NBD2 No No MgADP-
insensitive
Taschenberger
et al., 2002
Kir6.2
W91R M1 N.D. N.D. Unknown Crane and
Aguilar-Bryan,
2004
H259R C-term N.D. N.D. Unknown Marthinet et al.,
2005
E282K C-term N.D. N.D. Unknown Taneja et al.,
2009
R301G C-term N.D N.D Inactivation4 Lin et al., 2008
R301H C-term N.D N.D Inactivation Lin et al., 2008
R301P C-term N.D N.D Inactivation Lin et al., 2008
1Only published mutations that have been tested for surface expression are
included.
2These mutations were rescued to the cell surface by mutating the RKR ER
retention signal to AAA.
3N.D.: Not determined.
4Inactivation: Spontaneous current decay in the absence of inhibitory ATP.
ER quality control and allow surface expression of mutant chan-
nels that would otherwise be retained intracellularly (Drumm
et al., 1991). In addition to protein misfolding, recently a Kir6.2
mutation E282K identified in a case of histological focal CHI
(due to combination of a paternal KATP mutation and clonal
loss of heterozygosity of 11p15) was reported to diminish sur-
face expression of KATP channels by disrupting a di-acidic ER
exit signal in Kir6.2 involved in concentration of the channel pro-
tein into COPII vesicles without affecting channel protein folding
(Taneja et al., 2009). Also, the SUR1 mutation R1394H report-
edly causes retention of the channel in the Golgi compartment
of HEK239 cells, thereby preventing surface expression (Partridge
et al., 2001). Although increased internalization and degradation
of surface channels may also reduce the number of channels at the
cell surface no such examples have been reported.
CORRECTION OF KATP CHANNEL TRAFFICKING DEFECTS BY
PHARMACOLOGICAL CHAPERONES
The discovery that protein misfolding is an important cause of
various diseases has prompted intense investigation into ways of
overcoming the biogenesis defect as a means of therapy (Powers
et al., 2009). A key finding came from Denning et al, who showed
that cells expressing F508-CFTR had greater surface levels of
the channel when grown at reduced temperature (Denning et al.,
1992). This demonstrated that manipulation of the cellular fold-
ing environment can positively impact the biogenesis of proteins.
Certain exogenous compounds, like glycerol or DMSO, were also
shown to enhance the expression of trafficking-impaired proteins,
acting as chemical chaperones (Brown et al., 1996). It is thought
these compounds interact directly with the protein during folding
and assembly in the ER and impact biogenesis by one or several of
the following mechanisms: (1) reducing degradation by thermo-
dynamically stabilizing a misfolded conformation of the protein;
(2) increasing the folding rate by stabilizing a folding interme-
diate; (3) decreasing the misfolding rate by stabilizing the native
state. Alternatively, chemical chaperones could indirectly affect
biogenesis of proteins by interacting with endogenous molecular
chaperones in the ER.
Chemical chaperones, such as glycerol, are nonspecific, how-
ever, and enhance the expression of multiple proteins in a cell.
In a seminal study, Loo et al. demonstrated that pharmacolog-
ical ligands can specifically promote the stability and expres-
sion of trafficking-impaired mutant isoforms of P-glycoprotein
(P-gp), a multidrug resistant protein (Loo and Clarke, 1997).
Multiple drug compounds known to directly interact with P-gp
rapidly enhanced expression of various engineered P-gp traf-
ficking mutants in a dose-dependent manner, producing func-
tional proteins at the plasma membrane. These results were soon
echoed by various other groups using high-affinity ligands for
lysosomal α-galactosidase A (Fan et al., 1999), the V2 vaso-
pressin receptor (Morello et al., 2000), the HERG (human ether-
a-go-go-related gene) potassium channel (Zhou et al., 1999),
among others. An emerging theme began to develop in which
specific chemical chaperones, termed pharmacological chaper-
ones, could be administered therapeutically in order to reverse
trafficking defects found in patients with complex diseases.
High-throughput screens have identified more advanced com-
pounds which can rescue mutants with more subtle trafficking
defects. Several promising hits are currently undergoing clini-
cal trials for treatment of lysosomal storage diseases, including
Fabry’s, Pombe’s, Tay-Sachs, and Gaucher’s diseases, as well as
CF. Discussed below are recent studies describing the functional
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restoration of trafficking-impaired KATP channels with the use of
small molecule correctors. These studies have added to our fun-
damental understanding of the biogenesis of KATP channels while
bringing forth a new therapeutic route for treating CHI. Further,
they have led to new understanding in the ways that pharma-
cological ligands interact with KATP channels and impact their
function.
CORRECTION OF KATP CHANNEL TRAFFICKING DEFECTS BY
SULFONYLUREAS
As with many diseases, a major challenge has been to define
how mutations in KATP channel subunits associated with CHI
promote disease. Some mutant channels had been shown to
be unresponsive to MgADP stimulation (Nichols et al., 1996b;
Shyng et al., 1998; Snider et al., 2013), while others produce non-
functional truncated proteins due to insertion of a stop codon
(Nestorowicz et al., 1997, 1998). An important discovery came
from Cartier et al., who showed that one KATP channel mutation
identified in CHI, F1388 in SUR1, prevented surface expres-
sion of the channel when expressed in COS cells (Cartier et al.,
2001). Interestingly, functional channel complexes were observed
when the ER retention signal RKR in F1388-SUR1 was mutated
to AAA, which can often allow some trafficking-impaired pro-
teins to escape the ER. This placed some forms of CHI now in
the same category as CF and other protein misfolding diseases,
whereby loss-of-function results from mislocalization of mutant
proteins. Subsequent work identified additional SUR1 mutations
in CHI patients that impair the proper trafficking of KATP chan-
nels, including L1544P, A116P, and V187D (Taschenberger et al.,
2002; Yan et al., 2004).
The successful use of pharmacological ligands in correcting
trafficking defects of other membrane proteins prompted sev-
eral groups to apply that same principle to trafficking-impaired
KATP channels. Yan et al. (2004) demonstrated that two CHI
mutations, A116P andV187D, both located in the first transmem-
brane domain TMD0 of SUR1, could be rescued by sulfonylureas
in vitro. Functional study of mutant channels rescued to the cell
surface by the reversible sulfonylurea tolbutamide revealed nor-
mal sensitivity to MgADP and ATP once tolbutamide was washed
out, suggesting that trafficking mutations may not interfere with
channel function. Presumably, as is the case for pharmacological
rescue of other trafficking-impaired proteins, sulfonylureas facil-
itate the biogenesis of these SUR1 mutants by interacting with
the protein directly during folding and assembly in the ER. Yet an
understanding of the mechanism of the trafficking impairment
is key to grasping the mechanism of recovery. Previously, Chan
et al. showed that TMD0 domain of SUR1 harboring the A116P
or V187D mutation, had reduced association with Kir6.2 in co-
immunoprecipitation experiments (Chan et al., 2003). As TMD0
is known to mediate interactions between SUR1 and Kir6.2, it
is reasonable to assume that mutations in TMD0 disrupt these
subunit interactions and prevent channel trafficking out of the
ER. Yan et al. showed, however, that the trafficking defect in
A116P and V187D is intrinsic to SUR1. This is based on the
observation that in the absence of Kir6.2, A116P and V187D
also prevented Kir6.2-independent surface expression of a SUR1
protein in which the RKR ER retention signal is inactivated by
mutation to AAA (SUR1AAA). Another potential explanation for
the trafficking defect is that these mutations may prevent proper
shielding of the RKR ER retention signals that must occur dur-
ing assembly in the ER, as has been demonstrated for the L1544P
mutation (Taschenberger et al., 2002). Yet mutation of these sig-
nals in both subunits also failed to improve surface expression of
the A116P or V187D mutants. These results suggest that SUR1
misfolding, which also likely adversely affects association with
Kir6.2, prevents exit of these mutants from the ER. Consistent
with this notion, channel trafficking defects caused by A116P and
V187D could be overcome by culturing cells at lower temperature
(Yang et al., 2005), a condition known to facilitate protein folding.
Metabolic pulse-chase experiments demonstrated that gliben-
clamide slowed A116P-SUR1 degradation even in the absence
of Kir6.2 and promoted maturation of the mutant SUR1 when
Kir6.2 was co-expressed (Yan et al., 2004), providing evidence
that sulfonylureas facilitate folding and/or prevent misfolding of
mutant channels during assembly in the ER.
The question remained, however, of whether sulfonylureas
act as true pharmacological chaperones by promoting biogene-
sis through direct binding of the channel. Compelling evidence
came from a study showing that mutation of residues critical for
sulfonylurea and glinide binding abolished or reduced these com-
pounds’ ability to rescue KATP channel trafficking mutants (Yan
et al., 2006). Binding of tolbutamide, a first generation sulfony-
lurea, has been shown to depend on S1238 in SUR1, representing
site A (Ashfield et al., 1999). Accordingly, mutation of S1238 to
tyrosine abolished tolbutamide rescue of SUR1 mutants A116P
and V187D. Glibenclamide binding involves both site A (S1238)
and site B, which includes residue Y230 (Bryan et al., 2004).
Mutation of either site A (S1238Y) or site B (Y230A) dimin-
ished glibenclamide’s rescue effect, while simultaneous mutation
of both completely abolished it, suggesting that the sulfonylurea
and benzamido moieties both contribute to the rescue effect of
glibenclamide. Interestingly, the site B mutation Y230A, in addi-
tion to attenuating the effect of glibenclamide and abolishing the
effect of rapaglinide, also rendered tolbutamide ineffective at res-
cuing mutant channels. This suggests that either Y230 is involved
in tolbutamide binding or Y230 is necessary for post-binding
events involved in tolbutamide rescue, such as coupling of SUR1
and Kir6.2 subunits. In support of the latter, Y230 has been shown
to be in close proximity to the N-terminus of Kir6.2 (Vila-Carriles
et al., 2007). Further, deletion of the Kir6.2 N-terminus abol-
ishes tolbutamide channel block in membrane patches (Koster
et al., 1999; Reimann et al., 1999), suggesting a functional inter-
face at Y230 of SUR1 and the N-terminus of Kir6.2 that couples
tolbutamide binding to changes in channel activity. The results
of S1238Y and/or Y230A mutants on the ability of sulfonylureas
to rescue KATP trafficking mutants were also in parallel to their
ability to block channel activity. Thus, there is likely a common
mechanism in transducing ligand binding to functional outcome.
Finally, a key finding from this study is that sulfonylureas act
on the channel complex, rather than SUR1 alone, to restore sur-
face expression of trafficking mutants, as pharmacological rescue
by sulfonylureas is dependent on Kir6.2. Expression of either
A116PAAA-SUR1 or V187DAAA-SUR1, which lack the RKR ER
retention motif, could not be rescued without co-expression of
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Kir6.2. The requirement of Kir6.2 for the rescue effect could be
explained by the involvement of Kir6.2 in sulfonylurea binding to
SUR1; alternatively, Kir6.2 could participate in the tertiary folding
of mutant SUR1 subunits.
An interesting trend noted for all KATP trafficking mutants
tested thus far is that only mutations within TMD0 of SUR1 are
amenable to pharmacological rescue by sulfonylureas (Table 1).
TMD0, the first of three transmembrane domains in SUR1, is a
unique structural feature not shared by most ABC transporters,
including CFTR or P-gp, which contain only TMD1 and TMD2.
When expressed alone, TMD0 has been shown to physically asso-
ciate with Kir6.2 and both facilitate its expression and modulate
its gating function, making this domain a distinct functional
entity (Babenko and Bryan, 2003; Chan et al., 2003). The studies
described above demonstrate that sulfonylureas exert chaperon-
ing effects by binding regions downstream of TMD0. Thus, ligand
binding to the core ABC structure is likely translated into struc-
tural and functional outcomes at TMD0 to overcome trafficking
defects caused by mutations within this region. Such substrate-
induced transmembrane domain interactions have been reported
previously: in human P-gp, also an ABC transporter, substrate
binding promoted superfolding of partially folded intermediates
via interactions between the two transmembrane domains TMD1
and TMD2 (Loo and Clarke, 1998). As such, a likely mecha-
nism for the pharmacological chaperone effect is that sulfonylurea
binding to the SUR1/Kir6.2 complex induces structural changes
in TMD0 that restore functional interactions between SUR1 and
Kir6.2, allowing trafficking of the channel out of the ER. The pre-
cise nature of the interface between TMD0 and Kir6.2 is unclear,
however. Interestingly, a recent study by Zhou et al. showed that
a point mutation in Kir6.2, Q52E, located in the N-terminus of
the protein just before the slide helix, partially compensated for
the trafficking defects caused by SUR1-TMD0 mutations F27S
and A116P, indicating that altered molecular interactions with
Kir6.2 can overcome impaired channel folding/assembly caused
by TMD0 mutations (Zhou et al., 2013). An understanding of
how these domains are interacting will provide valuable insight
into not only the mechanism of pharmacological rescue, but also
how physiological or pharmacological interactions at SUR1 are
coupled to changes in channel activity at Kir6.2.
CORRECTION OF KATP CHANNEL TRAFFICKING DEFECTS BY
F508-CFTR CORRECTORS, IN PARTICULAR BY CARBAMAZEPINE
The fact that multiple TMD0 trafficking mutants have nor-
mal responses to metabolic signals and pharmacological ligands
provides proof of principle that pharmacological rescue is a ther-
apeutically viable alternative to the current treatment for many
CHI with such mutations, which often relies on partial or near
complete removal of the pancreas. Translation of these findings,
however, has been hindered by the pharmacology of gliben-
clamide, the most effective sulfonylurea at rescuing trafficking-
impaired KATP channels. SUR1 binds glibenclamide with high
affinity and slow dissociation kinetics, resulting in an irreversible
block on channel function; rescued channels would therefore be
unable to hyperpolarize the β-cell in order to attenuate insulin
release. Tolbutamide, another sulfonylurea that effectively res-
cues multiple TMD0 trafficking mutants, binds KATP channels
reversibly. A study released by the University Group Diabetes
Program, however, implicated tolbutamide in increased mortality
secondary to cardiovascular events (Schwartz andMeinert, 2004).
Thus, in terms of therapy, there is a need for additional com-
pounds that promote robust recovery of KATP channel trafficking
mutants and bind reversibly, but are also safe for administration
to patients.
Like trafficking-impaired KATP channels in CHI,F508-CFTR
causes partial misfolding of the channel and clearance through
the ubiquitin/proteasome pathway, resulting in CF. Much effort
has been devoted to identifying small molecules that correct
this trafficking defect, and high-throughput drug screens have
yielded several promising compounds (Pedemonte et al., 2005;
Carlile et al., 2007). As CFTR and SUR1 are both members
of the ABC transporter superfamily and have common struc-
tural features in the ABC core domain, it is reasonable to
hypothesize that small molecules which correct folding and traf-
ficking defects in F508-CFTR might also rescue trafficking-
impaired KATP channels caused by mutations in SUR1. Powell
et al. first reported the effects of compounds known to stimu-
late CFTR trafficking on human β-cells lacking functional KATP
currents from CHI patients harboring various ABCC8 muta-
tions (Powell et al., 2011). Although it remains unknown how
these mutations impact channel trafficking and gating to cause
loss of channel activity, the study demonstrated that a F508-
CFTR corrector, 4-phenylbutyrate, could recover activities of
KATP channels in β-cells isolated from a patient bearing the
SUR1 compound heterozygous mutation Arg998X/Ser1449dup
(Powell et al., 2011). Additionally, the study showed that incu-
bation of β-cells from another patient bearing homozygous
ABCC8 intronic mutation c.1467+5G>A with a combination
of 3-isobutyl-1-methylxanthine (IBMX), forskolin, and phorbol
myristic acid (PMA), compounds expected to activate PKA and
PKC, for 1 h also led to increased channel activity. Because PKA
activation has been reported to promote trafficking of several
ion channels to the cell surface whereas PKC activation has been
reported to reduce surface KATP expression by diverting endocy-
tosed channels to lysosomal degradation (Manna et al., 2010),
the authors speculate that the positive effect of PKA activation
likely overrides the negative effects of PKC to lead to an over-
all increase in surface expression of KATP channels (Powell et al.,
2011). It is interesting to note that a role of PKA in KATP chan-
nel trafficking has indeed been reported. A study by Yang et al.
showed that glucose stimulation recruits β-cell KATP channels to
the cell surface in a PKA-dependent manner (Yang et al., 2007).
In addition, Chen et al. showed that PKA activation promotes
KATP channel trafficking to the surface in INS-1 rat insulinoma
cells by promoting F-actin depolymerization without affecting
overall channel protein levels (Chen et al., 2013a). The find-
ings by Powell et al. will undoubtedly stimulate future research
to harness the therapeutic potential of these compounds and to
understand the molecular mechanisms by which these molecules
restore functional expression of KATP channels in CHI patients.
A more recent study by Sampson et al. tested the effects of
multiple CFTR correctors identified in a chemical library screen
(Carlile et al., 2007) on the processing efficiency of two SUR1
trafficking mutants, A116P and V187D (Sampson et al., 2013).
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Among the compounds that improved the processing efficiency of
the two mutant SUR1 proteins is the drug carbamazepine (CBZ).
CBZ has been used for decades in the treatment of epilepsy, neu-
ropathic pain, as well as mental illnesses like bipolar disorder.
CBZ has a well-documented role as a sodium channel blocker,
but studies have shown effects on calcium channels as well as
GABA receptors (Ambrosio et al., 2002). Our group focused
attention on CBZ as a potential pharmacological chaperone for
SUR1 trafficking mutants, as it is approved by the Food and
Drug Administration and has an established biosafety profile.
In a recent report we demonstrated that CBZ effectively res-
cues multiple KATP trafficking mutations previously identified
in CHI (Chen et al., 2013b) (Figure 3C). Interestingly, as with
sulfonylureas, only mutations present in TMD0 of SUR1 were
amenable to pharmacological rescue by CBZ. This suggests sul-
fonylureas and CBZ may act through a common mechanism
to enhance surface expression of trafficking mutants, such as
by stabilizing interactions between TMD0 and Kir6.2. There are
studies showing, however, that CBZ can induce autophagy to
facilitate clearance of misfolded protein aggregates (Sarkar et al.,
2007; Hidvegi et al., 2010), which could in turn alleviate ER
stress and promote surface expression of trafficking mutants. This
raises the possibility that CBZ may enhance surface expression
of TMD0 trafficking mutants not by acting as a pharmacologi-
cal chaperone but by inducing autophagy. Disfavoring this idea,
inhibition of autophagy by chloroquine or Ly294002 did not
block CBZ’s ability to rescue KATP trafficking mutants. Moreover,
stimulation of autophagy by rapamycin or Li+ did not enhance
mutant KATP channel processing or expression. These results indi-
cate that CBZ most likely rescues mutant channels through an
autophagy-independent pathway.
A surprising and intriguing finding by Chen et al. is that CBZ
inhibits the activity of mutant channels rescued to the cell sur-
face, as demonstrated in 86Rb+ efflux experiments. Subsequent
electrophysiology experiments showed that CBZ inhibits chan-
nel activity when applied to the cytoplasmic face of isolated
membrane patches containing wild-type KATP channels. These
observations suggest that CBZ may act as a KATP channel antago-
nist, like sulfonylureas. Further characterization of the inhibitory
effect of CBZ by 86Rb+ efflux assays showed that the function
of rescued mutant channels could be completely recovered after
extensive washout (∼90min), similar to that observed for the
reversible, low-affinity sulfonylurea tolbutamide but not the irre-
versible high affinity sulfonylurea glibenclamide (Yan et al., 2004).
Because the effect of CBZ on mutant channel trafficking could be
detected at a concentration as low as 0.2μM (Chen et al., 2013b)
(see Figure 3C), it is conceivable that low doses of CBZ could be
used to rescue mutant channels to the cell surface without potent
inhibition of channel activity. Another approach to circumvent
the problem of chaperone inhibitors may be to simultaneously
apply correctors and compounds that boost the function of res-
cued proteins, referred to as potentiators (Rowe and Verkman,
2013). Indeed, we have found that while diazoxide is unable to
activate channels rescued by the irreversible antagonist gliben-
clamide, it significantly increased the activity of channels rescued
by CBZ in Rb efflux assays. In these experiments, CBZ was not
included in the 40-min efflux period so some CBZ was likely to
have dissociated from the rescued channels, as evidenced by a
small increase in efflux even without diazoxide; however, inclu-
sion of diazoxide during efflux further increased channel activity,
indicating that diazoxide can facilitate functional recovery of CBZ
rescued channels. Clinically, this has important implications, as it
has been proposed that small changes in KATP channel activity are
correlated with large differences in clinical outcome (Macmullen
et al., 2011). Interestingly, we have found that diazoxide pre-
cludes glibenclamide’s ability to rescue KATP trafficking mutants,
while it has no effect on the rescue of mutant channels by CBZ
when the drugs are co-administered. This further supports the
clinical feasibility of a combination therapy using a pharmaco-
logical chaperone and a channel activator to alleviate symptoms
in patients with CHI. Also important, the effects of CBZ were
observed in two physiologically relevant systems, namely the rat
β-cell line INS-1 and freshly isolated primary human β-cells.
Further, the concentrations at which CBZ is effective at rescuing
TMD0 trafficking mutants (10–50μM) is similar to those used to
block Na+ channels, suggesting the approved dosage prescribed
for CBZ will impact KATP channel expression. These data make
a compelling case for further exploration of CBZ as a potential
treatment for patients with certain forms of CHI.
Besides therapeutic implications, CBZ and glibenclamide dif-
fer markedly in their chemical structures and yet both rescue the
expression of only those KATP channels with traffickingmutations
in TMD0 of SUR1 and both inhibit KATP channel activity. An
intriguing question to address in the future is whether the closed
channel conformation rendered by these ligands represents a state
that favors forward trafficking.
THE ROLE OF DIAZOXIDE ON KATP CHANNEL TRAFFICKING
Ideally, a pharmacological chaperone would correct protein traf-
ficking defects without compromising or even enhance protein
function. In this regard, it is worth noting that the KATP channel
opener diazoxide has been reported to correct channel traffick-
ing defects caused by the SUR1 mutations R1394H (Partridge
et al., 2001). Using a stable HEK293 cell line co-expressing wild-
type or R1394H His-tagged hamster SUR1 and Kir6.2 tagged
at the C-terminus with a HMA (heart muscle kinase phospho-
rylation site)-FLAG epitope, Partridge et al. showed that the
mutant SUR1 failed to reach the cell surface and instead accu-
mulated in the trans-Golgi network, and that diazoxide was
able to restore surface expression of the R1394H mutant SUR1.
However, a subsequent study by Yan et al. using FLAG-tagged
R1394H mutant hamster SUR1 transiently co-expressed with
Kir6.2 in COS cells reported normal trafficking of the mutant
to the cell surface (Yan et al., 2004). Whether these different
results are due to the different constructs or cells used remain
to be resolved. Aside from the R1394H mutation reported by
Partridge et al., no other known trafficking mutations tested so
far are rescued by diazoxide (Yan et al., 2004, 2007; Chen et al.,
2013b). Also worth noting, Powell et al. showed that a diazox-
ide analog BPDZ 154 restored ATP-inhibited channel activity in
human β-cells from a CHI patient with the homozygous ABCC8
intronic mutation c.1467+5G>A after 24–48 h incubation. Since
it is not clear how this intronic mutation affects channel traf-
ficking and/or function, it remains to be determined whether
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BPDZ 154 enhances channel trafficking and/or gating to restore
function.
INTERPLAY BETWEEN CHANNEL EXPRESSION AND GATING
IN DISEASE MANIFESTATION
Although some TMD0 mutations only impair channel trafficking
such that pharmacological rescue of mutant channels to the cell
surface is expected to partially or fully restore channel function,
some impact both channel biogenesis and gating as exemplified
by the R74W and E128K mutations (Pratt et al., 2009). These
mutations result in CHI by preventing channel expression at
the cell surface. Upon rescue to the cell surface by tolbutamide
followed by washout, mutant channels exhibit reduced sensitiv-
ity to ATP inhibition, a gating defect commonly observed in
gain-of-function mutations associated with permanent neona-
tal diabetes (PNDM). Detailed analysis revealed that these two
mutations cause functional uncoupling between SUR1 and Kir6.2
by impairing the ability of SUR1 to hypersensitize Kir6.2 chan-
nels to ATP inhibition (Pratt et al., 2011). When these mutations
were introduced into the insulinoma cells INS-1 and rescued to
the cell surface by tolbutamide, subsequent washout of tolbu-
tamide led to cells with more hyperpolarized membrane potential
in the face of glucose stimulation (Pratt et al., 2009), similar
to β-cells with gain-of-function, diabetes-causing mutant KATP
channels.
Intuitively, trafficking defects are associated with loss of chan-
nel function and the disease CHI. However, it has been shown that
many mutations identified in PNDM (Gloyn et al., 2004; Proks
et al., 2004, 2005, 2006; Koster et al., 2005) also reduce chan-
nel biogenesis efficiency, including Q52R, V59G/M, R201C/H
and I296L in Kir6.2 (Lin et al., 2006a) as well as F132L in
SUR1 (Pratt et al., 2009) when expressed heterologously as
homomeric mutant channels (Table 2). It is interesting that
glibenclamide was also found to significantly improve surface
expression of heterologously expressed homomeric mutant chan-
nels (Lin et al., 2006a), again hinting at SUR1-Kir6.2 interactions
in sulfonylurea-mediated rescue. Whether CBZ also improves
surface expression of these PNDM mutations remains to be
determined. Because these PNDM mutations are dominant, het-
erozygous mutations with severe gating defects, a mutant channel
subunit can exert its gain-of-function gating effect by co-assembly
with the WT allele. In this scenario, the extent of expression
of mutant subunit in the cell surface channel population may
determine the extent of overall channel gating defect and thus,
disease severity as has been proposed for several PNDM muta-
tions, including V324M in SUR1 (Zhou et al., 2010) as well as
C42R and Pro226-Pro232 deletion mutation in Kir6.2 (Yorifuji
et al., 2005; Lin et al., 2013).
The above studies highlight the importance of the interplay
between channel expression and gating defects in determining
disease phenotype. As KATP conductance is a product of the num-
ber of channels in the β-cell membrane and the open probability
of the channel at a given metabolic state dictated by channel gat-
ing properties, correlation between channel defects and disease
phenotype would require thorough analysis of the impact of a
mutation on both channel expression and channel gating as well
as consideration of the genetic context of the mutation.
Table 2 | Neonatal Diabetes-associated KATP channel trafficking
mutations and response to sulfonylurea treatment.
Mutation Surface expression Gating References
increased by SU property
SUR1
F132L Yes Increased Po Pratt et al., 2009
V324M N.D. Increased MgADP
sensitivity
Zhou et al., 2010
Kir6.2
C42R N.D. Increased Po Yorifuji et al., 2005
Q52R Yes Increased Po Proks et al., 2004;
Lin et al., 2006a
V59G Yes Increased Po Proks et al., 2004;
Lin et al., 2006a
V59M Yes Increased Po Koster et al., 2005;
Lin et al., 2006a
R201C Yes Decreased ATP
inhibition
Proks et al., 2004;
Lin et al., 2006a
R201H Yes Decreased ATP
inhibition
Proks et al., 2004;
Lin et al., 2006a
Pro226_
Pro232del
N.D. Increased Po Lin et al., 2013
I296L Yes Increased Po Proks et al., 2005;
Lin et al., 2006a
CONCLUSIONS AND PERSPECTIVES
Pharmacological chaperones have emerged as promising thera-
peutic tools for treating diseases resulting from defective protein
folding and/or trafficking. Demonstration that sulfonylureas and
CBZ are effective pharmacological agents able to restore surface
expression of KATP trafficking mutants identified in congenital
hyperinsulinism has direct clinical relevance. As CBZ is an FDA-
approved drug, it may stand to rapidly improve current therapies
for patients harboring trafficking mutations within TMD0 of
SUR1. In order to spur translation of these findings into real
treatment, an important next step is to demonstrate the efficacy
of CBZ in β-cells isolated from CHI patients with KATP traf-
ficking mutations within TMD0. Also, currently only a subset
of identified TMD0 trafficking mutations associated with dis-
ease has been examined for their ability to be rescued by CBZ.
The therapeutic applicability of CBZ for treating KATP traffick-
ing disorders will likely expand in the future as more mutations
are identified and tested. Finally, although CBZ also inhibits KATP
channel function, this inhibition is reversible and can be partially
overcome by co-application of potentiators, such as diazoxide,
without compromising CBZ’s corrector effect. These findings
represent significant improvements over pharmacological rescue
using glibenclamide, but CBZ itself may only be a model demon-
strating the potential that future pharmacological correctors hold
for treating KATP channel trafficking disorders.
Beyond the therapeutic implications, in vitro studies utilizing
pharmacological chaperones and naturally occurring mutations
in KATP channel subunits have enhanced our understanding
of structure-function relationships in terms of biogenesis and
molecular assembly, as well as gating and coupling between
subunits. For instance, the finding that only trafficking mutations
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within TMD0 of SUR1 are amenable to pharmacological res-
cue further underscores the importance of this unique domain
in mediating subunit interactions with Kir6.2 and highlights a
role of TMD0 in channel assembly. The fact that drug bind-
ing, at least in the case of sulfonlylureas, to L0 and TMD2 of
SUR1 as well as N-terminus of Kir6.2 has functional consequences
for mutations within TMD0 suggests that either these domains
can physically interact or there is a mechanism for transducing
structural changes in trans to TMD0. Further, the fact that some
KATP trafficking mutants rescued by reversible inhibitors (CBZ,
tolbutamide) are functional upon drug washout and retain nor-
mal responses to metabolic signals and pharmacological ligands
implies that these residues in TMD0 are not involved in gating or
other functional aspects of the channel, but likely play important
roles in the folding of this domain or may even be key residues at
the interface of SUR1 and Kir6.2. At present, it is unclear whether
CBZ binds directly to the channel complex during biogenesis or
impacts channel expression and gating indirectly through interac-
tions with other proteins. If CBZ does interact directly, defining
the binding sites on KATP will provide valuable information on
the mechanism by which this drug modulates channel folding,
assembly and gating. This knowledge is critically important for
future efforts to design more effective drugs that will target
the biogenesis or gating defects of disease-causing mutant KATP
channels.
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